Experimental p38 MAPK inhibitors for the treatment of urological cancers: observations from early clinical trials.

INTRODUCTION

Adopted response in signals consists a cornerstone ability of cancer cells resulting in their survival and proliferation. Molecular pathways of MAPK and specifically p38/SAPKs regulate such responses. Recently, literature has come up with new trials about p38 MAPK inhibition as a possible pharmaceutic target in the treatment of urologic malignancies.

AREAS COVERED: The present report is a short review of the literature about existing data of the role of p38 molecular pathway in tumorigenesis and its possible inhibition during its treatment. Preclinical and clinical trials of p38 inhibitors are presented.

EXPERT OPINION: Molecular knowledge exists about inhibition of p38 pathway in the treatment of urologic malignancies. However, literature is lacking regarding effectiveness and safety profile of specific compounds. As a result, more trials are mandatory to reach a safe conclusion.